Kenneth Westover Lab Materials

The Kenneth Westover Lab has deposited materials at Addgene for distribution to the research community. Addgene is a nonprofit plasmid repository dedicated to improving life science research.

Learn more about research in the Kenneth Westover Lab.

If this is your lab: Add a depositor badge to your website.

• Plasmids
• Articles

Showing 1 to 7 of 7 entries

Show 102550100All entries

Search table:

• Previous
• 1
• Next

Title	Authors	Publication
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.	Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD	Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.
Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.	Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD	Cell Chem Biol. 2020 Oct 15;27(10):1229-1240.e4. doi: 10.1016/j.chembiol.2020.07.011. Epub 2020 Aug 4.
Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).	Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS	J Med Chem. 2015 Jan 8;58(1):183-96. doi: 10.1021/jm500480k. Epub 2014 Jul 30.
GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R).	Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD	Birth Defects Res. 2020 Mar 18. doi: 10.1002/bdr2.1647.
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.	Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaria D, Westover KD, Janne PA	Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.
Structural basis of the atypical activation mechanism of KRAS(V14I).	Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD	J Biol Chem. 2019 Sep 20;294(38):13964-13972. doi: 10.1074/jbc.RA119.009131. Epub 2019 Jul 24.
Tissue-Specific Oncogenic Activity of KRAS(A146T).	Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM	Cancer Discov. 2019 Jun;9(6):738-755. doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5.

Showing 1 to 10 of 14 entries

Show 102550100All entries

Search table:

• Previous
• 1
• 2
• Next

	ID	Plasmid	Gene/Insert	Vector Type	Publication
50.2.863666.111849	111849	pDNA2.0 6H-TEV-KRAS	KRAS (KRAS Human)	Bacterial Expression	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.
20.3.162234.111848	111848	pDNA2.0 6H-FLAG-TEV-KRAS G12C	KRAS G12C (KRAS Human)	Bacterial Expression	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.
20.1.128850.111850	111850	pDNA2.0 6H-TEV-KRAS G12V	KRAS G12V (KRAS Human)	Bacterial Expression	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.
20.0.525611.112718	112718	pcDNA3.1-YFP-KRAS4B	YFP-KRAS4B (KRAS Human)	Mammalian Expression	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.
	111851	pDNA2.0 6H-TEV-KRAS G13D	KRAS G13D (KRAS Human)	Bacterial Expression	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.
	112717	pcDNA3.1-CFP-KRAS4B	CFP-KRAS4B (KRAS Human)	Mammalian Expression	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.
	154426	KRAS-A146T	KRAS (KRAS Human)	Bacterial Expression	Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov. 2019 Jun;9(6):738-755. doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5.
	154427	KRAS-V14I	KRAS (KRAS Human)	Bacterial Expression	Structural basis of the atypical activation mechanism of KRAS(V14I). J Biol Chem. 2019 Sep 20;294(38):13964-13972. doi: 10.1074/jbc.RA119.009131. Epub 2019 Jul 24.
	154874	LIC4B-His-TEV-TAK1-TAB1	TAK1-TAB1 (TAB1 Human)	Insect Expression	Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. doi: 10.1021/jm500480k. Epub 2014 Jul 30.
	158527	KRAS-P34R	KRAS (KRAS Human)	Bacterial Expression	GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020 Mar 18. doi: 10.1002/bdr2.1647.